Genes and their polymorphisms in mono- and multifactorial cardiomyopathies: Towards pharmacogenomics in heart failure

Pharmacogenomics

Volumn 3, Issue 3, 2002, Pages 367-378

  Charron, Philippe ^a   Komajda, Michel ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Cardiomyopathy; Genetic testing; Genetics; Heart failure; Pharmacogenetics

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACTIN; ACTIN BINDING PROTEIN; ADENOSINE MONOPHOSPHATE DEAMINASE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CONNECTIN; DESMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DYSTROPHIN; ENDOTHELIN A RECEPTOR; HLA DR ANTIGEN; LAMIN A; LAMIN C; LOSARTAN; LOSARTAN POTASSIUM; MANGANESE SUPEROXIDE DISMUTASE; MYOSIN; PROTEIN C; SARCOGLYCAN; SIMVASTATIN; SPIRONOLACTONE; TRANDOLAPRIL PLUS VERAPAMIL; TRANSFORMING GROWTH FACTOR BETA1; TROPOMYOSIN; TROPONIN C; TROPONIN I; TROPONIN T; UNINDEXED DRUG; VERAPAMIL;

ANGIOCARDIOGRAPHY; ATHLETE; CARDIOMYOPATHY; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; GENETIC POLYMORPHISM; HEART DILATATION; HEART FAILURE; HEART HYPERTROPHY; HEART TRANSPLANTATION; HUMAN; INCIDENCE; MONOGENIC DISORDER; MULTIFACTORIAL GENETIC DISORDER; MYOCARDIAL DISEASE; NONHUMAN; PATHOGENESIS; PHARMACOGENOMICS; PHENOTYPE; PREVALENCE; RAT; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SOCIOECONOMICS; SUDDEN DEATH; TREATMENT INDICATION;

ANIMALS; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; HEART FAILURE, CONGESTIVE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0036265744     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.3.367     Document Type: Review

References (89)

1. Report of the 1995 World Health Organisation/International Society and Federation of Cardiology task force on the definition and classification of Cardiomyopathies
2. Idiopathic dilated cardiomyopathy
3. Hypertropic cardiomyopathy
4. Restrictive cardiomyopathy
5. Epidemiology of idiopathic dilated and hypertropic cardiomyopathy
6. The registry of the international society for heart transplantation: Seventh official report-1990
7. Factors predicting mortality in idiopathic dilated cardiomyopathy
8. The treatment of heart failure: The task force of the working group on heart failure of the european society of cardiology
9. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy
10. Familial dilated cardiomyopathy in the United Kingdom
11. Familial dilated cardiomyopathy: Cardiac abnormalities are common in asymptomatic relatives and may represent early disease
12. Familial dilated cardiomyopathy: Clinical features in French families
13. Guidelines for the study of Familial Dilated Cardiomyopathies
14. Familial dilated cardiomyopathy: Evidence for genetic and phenotypic hetrerogeneity
15. Familial agregation of idiopathic dilated cardiomyopathy: Clinical features and pedigree analysis in 14 families
16. Dystropinopathy, the expanding phenotype. Dystropin abnormalities in X-linked dilated cardiomyopathy
17. The role of cytoskeletal proteins in cardiomyopathies
18. Mitochondria and heart disease
19. Prevalence and characteristics of dystropin defects in adult male patients with dilated cardiomyopathy
20. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease
21. Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23
22. Dilated cardiomyopathy and sensorineural hearing loss: A heritable syndrome that maps to 6q23-24
23. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23
24. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement
25. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms
26. Complexity in simplicity: Monogenic disorders and complex cardiomyopathies
27. Deletion of the dystropin muscle-promoter region associated with X-linked dilated cardiomyopathy
28. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure
29. Desmine mutation responsible for idiopathic dilated cardiomyopathy
30. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy
31. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy
32. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy
33. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy
34. Desmin and cardiac actin gene mutations are uncommon in a European population of dilated cardiomyopathy
35. A new locus for autosomal dominant dilated cardiomyopathy identified on chromosome 6q12-q16
36. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy
37. Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy
38. Lack of association between polymorphisms of eight candidate genes in idiopathic dilated cardiomyopathy
39. Characterization of a unique genetic variant in the beta 1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy
40. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy: Involvement of a polymorphism in the endothelin receptor type A gene
41. Association of a G994T missense mutation in the plasma platelet-activating factor acethylhydrolase gene with genetic susceptibility to non familial dilated cardiomyopathy in Japanese
42. Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in japanese
43. Beta1-adrenoceptor gene variations: A role in idiopathic dilated cardiomyopathy?
44. Haemochromatosis gene mutations in idiopathic dilated cardiomyopathy
45. Idiopathic dilated cardiomyopathy: Lack of association with haemochromatosis gene in the CARDIGENE study
46. Characterization of the human nebulette gene: A polymorphism in an actin-binding motif is associated with nonfamilial idiopathic dilated cardiomyopathy
47. TGF-beta1 gene polymorphisms in patients with end stage heart failure
48. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure
49. The Ile164 beta 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure
50. Common variant in AMPD1 gene predicts imporoved clinical outcome in patients with heart failure
51. A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure
52. A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy
53. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction
54. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure
55. Bradykinin B2 receptor gene polymorphism is associated with angiotensin converting enzyme inhibitor-related cough
56. Pharmacogenetics of β1 and β2 adrenergic receptors
57. Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure
58. Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors
59. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure
60. Prevalence of hypertropic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (young) adults
61. Patterns of inheritance in hypertropic cardiomyopathy: Assessment by M-mod and two-dimensional echocardiography
62. The molecular genetic basis for hypertropic cardiomyopathy
63. Familial hypertropic cardiomyopathy: From mutations to functional defects
64. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertropic cardiomyopathy: Evidence for the central role of energy compromise in disease pathogenesis
65. Characteristics and prognostic implications of myosin missense mutations in familial hypertropic cardiomyopathy
66. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertropic cardiomyopathy
67. Clinical features and prognostic implications of familial hypertropic cardiomyopathy related to the cardiac myosin binding protein C gene
68. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertropic cardiomyopathy
69. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertropic cardiomyopathy
70. The influence of the angiotensin I converting enzyme genotype in familial hypertropic cardiomyopathy varies with the disease gene mutation
71. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertropic cardiomyopathy
72. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertropic cardiomyopathy
73. Variants of tropic factors and expression of cardiac hypertrophy in patients with hypertropic cardiomyopathy
74. Association of a G994→T (Val279→Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertropic cardiomyopathy
75. Genotype-phenotype analysis in four families with mutations in β-myosin heavy chain gene responsible for familial hypertropic cardiomyopathy
76. New concepts in hypertropic cardiomyopathies
77. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
78. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy
79. Absence of association or genetic linkage between the angiotensin converting-enzyme gene and left ventricular mass
80. Association of the angiotensin converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training
81. Human gene for physical performance
82. Genetic variants of proteins from the renin angiotensin system are associated with pressure load cardiac hypertrophy
83. Prediction of left ventricular mass changes after renal transplantation by polymorphism of the angiotensin-converting-enzyme gene
84. Application of industrial scale genomics to discovery of therapeutic targets in heart failure
85. Functional genomics and cardiovascular drug discovery
86. Etiologies of cardiomyopathy and heart failure: Evidence for a final common pathway for disorders of the myocardium
87. Investigation of a family with autosomal dominant dilated cardiomyopathy defines a novel locus on chromosome 2q14-q22
88. Linkage of familial dilated cardiomyopathy to chromosome 9
89. A familial disorder of automaticity and conduction associated with cardiomyopathy maps to chromosome 3p